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End-stage renal disease (ESRD) is a major public health problem,
affecting 1 in 1,000 individuals and with an annual death rate of
20% despite dialysis treatment1,2. IgA nephropathy (IgAN) is the
most common form of glomerulonephritis, a principal cause of
ESRD worldwide1,2; it affects up to 1.3% of the population3–6
and its pathogenesis is unknown. Kidneys of people with IgAN
show deposits of IgA-containing immune complexes with prolif-
eration of the glomerular mesangium (Fig. 1). Typical clinical fea-
tures include onset before age 40 with haematuria and
proteinuria (blood and protein in the urine), and episodes of
gross haematuria following mucosal infections are common;
30% of patients develop progressive renal failure6–9. Although
not generally considered a hereditary disease, striking ethnic
variation in prevalence1–6,10 and familial clustering11–16, along
with subclinical renal abnormalities among relatives of IgAN
cases9,14–16, have suggested a heretofore undefined genetic
component. By genome-wide analysis of linkage in 30 multiplex
IgAN kindreds, we demonstrate linkage of IgAN to 6q22–23
under a dominant model of transmission with incomplete pene-
trance, with a lod score of 5.6 and 60% of kindreds linked. These
findings for the first time indicate the existence of a locus with
large effect on development of IgAN and identify the chromoso-
mal location of this disease gene.
We studied multiplex IgAN kindreds from Italy (24 kindreds) and
the United States (6 kindreds). All were ascertained through
biopsy-documented IgAN cases and had at least one more affected
member. Relatives provided medical records and were screened for
haematuria, proteinuria and renal function. Relatives were classi-
fied as affected if they had IgAN on renal biopsy, or, alternatively,
haematuria (≥5 red blood cells/high power field) or proteinuria
Table 1 • Lod scores for linkage of IgAN to candidate loci
Locus location (cM) Nearest loci (cM) Multipoint Multipoint
lod (α=1) lod (α=0.5)
Ig κ-chain cluster 2p12 (115) D2S2972 (114) –6.9 –0.3
D2S340 (120)
Ig λ-chain cluster 22q11 (14) D22S420 (15) –2.6 –0.45
GCT10C10 (18)
Ig heavy chain cluster 14q32.3 (124) GATA168F06 (113) –3.5 –0.05
GATA136B01 (126)
Ig joining chain 4q25 (77) D4S3248 (70) –4.5 0.3
D4S2367 (78)
MHC 6p21.3 (45) GATA163B10 (43) –8.0 –0.5
D6S1281 (44)
galactosyltransferase
T1 2q32 (182) D2S1776 (173) –4.5 0.3
D2S1391 (186)
T2 1q31 (209) D1S518 (202) –2.9 –1.8
D1S1660 (212)
T3 3q25 (178) D3S1763 (176) –4.8 –2.5
D3S2440 (181)
T4 6p21 (45) GATA163B10 (43) –8.0 –0.5
D6S1281 (44)
IgA Fc receptor (CD89) 19q13.4 (97) D19S589 (88) –2.8 0.5
D19S210 (100)
uteroglobin 11q13 (65) D11S1985 (58) –11.5 –1.1
D11S1765 (62)
D11S1883 (65)
Lod scores for linkage of IgAN to indicated candidate loci are shown under dominant models of transmission specify-
ing locus homogeneity or heterogeneity with α=0.5.
a
b
Fig. 1 Pathology of IgAN. A section
of a renal biopsy of a patient with
IgAN is shown. a, Periodic acid Schiff
staining of a glomerulus revealing
mesangial expansion and prolifera-
tion. b, Immunofluorescence staining
of a glomerulus with anti-IgA anti-
serum demonstrating IgA deposition
in the mesangium.
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(≥3+ proteinuria on urine dipstick) on at least three occasions, or
ESRD without other identifiable causes. Relatives ≥40 years with
normal urinalysis and no history of renal disease were classified as
unaffected; unaffected relatives <40 years were classified as pheno-
type unknown. The 30 kindreds included 94 affected members, 48
unaffected members and 21 with phenotype unknown owing to
young age (Fig. 2). Among affected members, 60 had biopsy-docu-
mented IgAN (12 with ESRD), 29 had persistent haematuria/pro-
teinuria (16 with episodic gross haematuria) and 5 had idiopathic
ESRD. The mean age of diagnosis was 33 years and the male:female
ratio was 1.5:1. All phenotypes were assigned prospectively before
initiation of genotyping. The familial clustering in these pedigrees
is consistent with multifactorial determination or autosomal dom-
inant transmission with reduced penetrance.
Suggested abnormalities in IgAN have included a maladaptive
immune response or altered structure or clearance of IgA (refs
8,9). Consequent candidate genes include the immunoglobulin
genes9,17, the major histocompatibility locus9,18, the galactosyl
transferases8,19, the IgA Fc
receptor20 (CD89) and utero-
globin21. Accordingly, we geno-
typed polymorphic markers
closely linked to these genes.
Analysis of the results did not
provide evidence of linkage of
IgAN to any of these loci under
parametric or non-parametric
models (Table 1). Because
gene-targeting studies in mice
have raised uteroglobin as a
candidate21, we also screened
the coding sequence of this
gene for mutations but identi-
fied none. These findings do
not implicate any of these can-
didate loci in familial IgAN.
We next carried out a
genome-wide analysis of link-
age, genotyping polymorphic
markers distributed at 10-cM
intervals. To test for a locus
Fig. 2 IgAN kindreds. The structures of 4 of the 30 multiplex IgAN kindreds are shown. Affected individuals are indicated by
the filled symbols, unaffected individuals by unfilled symbols and individuals of phenotype unknown (unaffected with age
<40) by shaded symbols. Dotted symbols denote individuals who were not studied and were classified as phenotype
unknown. Deceased individuals (diagonal lines) are of unknown phenotype unless indicated by filled symbols. Below the
symbol for each individual, genotypes for 15 markers at 6q22–23 are shown in their chromosomal order. The identity of each
marker and the distance between adjacent loci is indicated in the box at the upper left. Inferred haplotypes shared by rela-
tives with IgAN are indicated by boxes. Below each kindred number, the multipoint lod score for linkage to IGAN1 at
D6S1040 under the dominant model is shown. Pedigrees and genotypes for remaining kindreds are available (Figs A–D, see
http://genetics.nature.com/supplementary_info/).
Table 2 • Pairwise lod scores
for linkage of markers at
6q22–23 to IgAN
Locus Location (cM) lod (θ)
D6S474 119 1.6 (0.14)
D6S423 120 0.3 (0.23)
D6S979 122 0.2 (0.30)
D6S1712 123 0.1 (0.41)
D6S408 124 0.1 (0.05)
D6S1702 125 3.3 (0.01)
D6S1715 126 0.1 (0.40)
D6S1958 126 1.5 (0.08)
D6S407 127 2.9 (0.05)
D6S1690 127 0.4 (0.22)
D6S1705 129 2.5 (0.04)
D6S1040 129 3.7 (0.00)
AF196xH1 129 3.0 (0.00)
AF162GT1 130 0.9 (0.14)
D6S1572 130 1.4 (0.13)
D6S262 130 0.7 (0.14)
D6S457 131 1.5 (0.14)
D6S1656 132 1.9 (0.14)
D6S472 133 1.1 (0.06)
D6S413 133 0.9 (0.13)
D6S1038 135 1.0 (0.01)
D6S270 137 0.5 (0.15)
D6S1272 137 0.2 (0.40)
D6S1009 139 1.1 (0.10)
Maximum lod scores for linkage of
indicated loci to IgAN at indicated
recombination fractions (θ) in all 30
kindreds under the dominant model
of transmission are shown.
D6S474
D6S979
D6S1712
D6S1702
D6S1958
D6S1690
D6S1705
D6S1040
AF196xH1
D6S1572
D6S457
D6S1656
D6S472
D6S1038
D6S1009
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Fig. 3 Linkage of IgAN to
6q22–23. The location of 24
polymorphic marker loci across
6q22–23 that were used in mul-
tipoint linkage are shown at
the top of the figure. Below,
the multipoint lod and NPL
scores for linkage of IgAN
across this interval in the 30
IgAN kindreds are shown. The
multipoint lod score was cal-
culated under the dominant
model of transmission with
incomplete penetrance allow-
ing for locus heterogeneity.
The filled bar indicates the
lod-1 support interval for
IGAN1.
with large effect on the
trait, we carried out
multipoint analysis of
linkage under models of
locus homogeneity or
heterogeneity, specify-
ing IgAN as an autoso-
mal dominant trait with
disease allele frequency
of 0.001, phenocopy
rate of 0.01 and esti-
mated penetrance of
75%. Analysis identified
no interval with lod
score greater than 1.0
under locus homogene-
ity; under models of
locus heterogeneity, five intervals yielded initial multipoint lod
scores greater than 1.0. Following typing of further markers in
each interval, the lod score remained greater than 1.0 in two
intervals. One locus, which we now call IGAN1, is located at
6q22–23. We genotyped 24 polymorphic markers in the 20-cM
interval bounded by loci D6S474 and D6S1009. All yielded pos-
itive lod scores in pairwise analysis, with a maximum lod score
of 3.7 at D6S1040 (Table 2). Multipoint linkage including all
loci typed on chromosome 6 yielded a maximum lod score of
5.6 at D6S1040 with an estimated 60% of kindreds linked (Fig.
3 and Table 3). This lod score exceeds the threshold of 3.28 for
significant linkage in the setting of locus heterogeneity and has
approximately the same significance as a lod score of 5.3 under
models of locus homogeneity22. The lod -1 support interval
places IGAN1 in the 6.5-cM interval between D6S1702 and
D6S262.
This evidence for linkage is robust to alternative analyses. The
lod score remains greater than or equal to 5.0 for penetrance
estimates ranging from 20% to 85% and for phenocopy rates
ranging from 0.03 to 0.0001. The lod score remains 5.2 (α=0.59)
in analysis of affected members only. Similarly, non-parametric
analysis of allele-sharing among affected individuals achieves a
non-parametric lod (NPL) score of 5.1 (P=4.8×10–6; Fig. 3),
which is significant at the genome-wide level23. Secondary
analysis using a more stringent phenotype, classifying as affected
only biopsy-documented cases plus those with either episodic
gross haematuria or idiopathic ESRD, continues to provide
strong evidence of linkage at IGAN1 (multipoint lod score 5.5,
α=0.65). Both Italian (lod score 3.2, α=0.50) and US kindreds
(lod score 2.7, α=0.98) contribute and show peak lod scores in
the same interval. Locus homogeneity is 1,000-fold less likely
than locus heterogeneity, and recessive models of transmission
at IGAN1 are rejected.
The other interval with lod score greater than 1.0 lies at
3p23–24; this interval did not reach statistical significance (lod
score 2.8, α=0.33; NPL score 2.9, P=0.003), and this result was not
altered by multilocus analysis. Re-analysis of genome-wide data in
kindreds partitioned into those with positive or negative lod
scores at IGAN1 did not yield further loci suggestive of linkage.
These results provide highly significant evidence for linkage of
IgAN to 6q22–23 under a dominant model with incomplete pen-
etrance and locus heterogeneity. The observed reduced pene-
trance is compatible with an inherited susceptibility whose
expression is dependent on environmental or genetic modifiers.
There are no apparent clinical or demographic features that dis-
tinguish families with positive or negative lod scores at IGAN1.
IGAN1 lies 80 cM distal to the major histocompatibility locus.
Examination of sequence databases indicates that the linked
interval does not contain any compelling candidates for IgAN. So
far, we have found no evidence of linkage disequilibrium between
marker alleles at 6q22–23 and IgAN.
Progress in identification of the IGAN1 gene can proceed on
several fronts. Genes identified in this interval can be tested for
their role in IgAN and polymorphisms can be used to search for
linkage disequilibrium. It is of interest that although IgAN is the
most common renal disease among the Zuni native Americans11,
it is rare in individuals of African ancestry10. These observations
suggest use of linkage disequilibrium and admixture disequilib-
rium mapping in IgAN cases in these respective populations24.
Identification of the molecular defect underlying IGAN1 may
provide insight into the pathogenesis, diagnosis and treatment of
this cause of renal failure.
Table 3 • Multipoint lod
scores for linkage to IGAN1
in individual kindreds
Kindred Multipoint
lod at IGAN1
124 1.70
142 1.49
122 1.28
123 1.28
107 0.80
131 0.73
104 0.69
100 0.59
160 0.55
102 0.50
129 0.29
103 0.29
108 0.19
171 0.12
176 0.11
111 0.05
133 0.05
174 0.02
121 –0.02
127 –0.15
125 –0.15
126 –0.24
175 –0.25
109 –0.55
136 –0.90
172 –1.00
173 –1.00
128 –1.20
101 –1.30
106 –1.50
The lod score for linkage of IgAN to
the IGAN1 locus under the dominant
model of transmission is shown for
each kindred studied.
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Methods
Patients. We ascertained IgAN kindreds through index cases with biopsy-
documented disease. Relatives were also examined. Eight Italian kindreds
were from the Brescia district of northern Italy and 16 were of diverse geo-
graphic origin in Italy. Four kindreds in the US were from Kentucky, one
was from Connecticut and one was from Washington State. Eighteen kin-
dreds have been reported9,12–16; the relationship of these kindreds to those
reported previously is indicated (Table A, see http://genetics.nature.com/
supplementary_info/). The study was approved by the Human Investiga-
tion Committee at Yale University.
Genetic analysis. We prepared genomic DNA from venous blood of kin-
dred members as described25. We initially genotyped 384 highly polymor-
phic markers distributed at intervals of approximately 10 cM using fluores-
cent primers to direct PCR from genomic DNA followed by fractionation
and data collection using an ABI 377 DNA sequencer25. Investigators
blinded to affection status scored all genotypes using the Genotyper 1.1.1
software. Gene and marker locations were specified according to databases
at the National Center of Biotechnology Information, the Whitehead Insti-
tute for Genomic research and the Genome Database web sites.
We carried out analysis of linkage under parametric and non-paramet-
ric models, and pairwise and multipoint parametric analysis using LINK-
AGE (ref. 26) v. 5.0 and GENEHUNTER (ref. 27) v. 2.0, respectively. We
specified a dominant model of transmission with reduced penetrance
(estimated at 75%), allowing for locus heterogeneity with disease allele
frequency of 0.001 and phenocopy rate of 0.01 (in secondary analysis
using a more stringent phenotype, the phenocopy rate was accordingly
reduced to 0.001). NPL scores were calculated using GENEHUNTER.
Intervals showing NPL or lod scores >1 in the initial genome-wide analy-
sis as well as several candidate loci were analysed in further detail by typ-
ing additional markers. Allele frequencies at marker loci were specified
according to their frequency in the families studied; owing to the high
marker density, changing the estimates of allele frequencies had little
effect on the resulting multipoint lod scores at IGAN1. Likelihood ratios
of linkage under models of locus heterogeneity were calculated as LR =
αLR (θ1) + (1–α), where θ1 is the location of the trait locus and α is the
proportion of families linked to θ1. Multilocus lod scores were calculated
as LR = αLR (θ1) + βLR(θ2) + (1–α–β), where β corresponds to the pro-
portion of families linked to θ2.
To search for linkage disequilibrium, we compared the frequencies of
independent alleles segregating with IGAN1 with those found on indepen-
dent unlinked chromosomes. Italian and US kindreds were analysed sepa-
rately using the DISEQIN program28.
To search for mutations in the uteroglobin gene, we used primers located in
introns to direct amplification of the coding sequences of this gene by PCR
(exon 1, F, 5´–GACGGAACCAGAGACGGGCCAGAGCAT–3´, R, 5´–CTGA
GACTCAGCATGCCCAG–3´; exon 2, F, 5´–CTTCTCTCCTCTGTGTTGCA
–3´, R, 5´–CTTGGGGAAGCCACTTCTAACCAG–3´; exon 3, F, 5´–TCCTCC
TAGAGTTGACTGCAC–3´, R, 5´–GTGGACTCAAAGCATGGCAGCGGC
–3´; ref. 29). The products were analysed by single-stranded conformational
polymorphism analysis, as described30.
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